Abstract
Bisphosphonates have recently been introduced in the therapeutic armamentarium for long-term treatment of patients with multiple myeloma. These pyrophosphate analogs not only reduce the occurrence of skeletal events but also provide clinical benefit to patients and improve the survival of some of them. The existence of these capabilities raises the possibility that these compounds may have a direct antiproliferative effect on tumor cells. To investigate whether these drugs exert a direct antitumor effect, we exposed human myeloma cell lines ARH-77 and RPMI-8226 to increasing concentrations of zoledronic acid (ZOL) in vitro. A concentration- but not time-dependent cytotoxic effect was detected with drug treatment of ARH-77 and RPMI-8226 cell lines (30% and 60% at 48 hours and 38% and 62% at 72 hours, respectively, for 50µM of ZOL). Cytotoxicity was not due to ZOL-induced chelation of extracellular calcium as shown by control experiments with the calcium chelator ethylene glycol-bis(β-aminoethylether)-N,N,N’,N’-tetraacetic acid. Addition of the competitive inhibitor of the nitric oxide synthase Nω-nitro-L-arginine methyl ester did not modulate ZOL-induced cytotoxicity. However, a decrease in the number of apoptotic cells was detected when protein kinase C was inhibited by addition of staurosporine to ZOL-containing cultures. Cytotoxicity also was increased by addition of dexamethasone (Dex) and thalidomide (Thal) to ARH-77 and RPMI-8226 cultures. We demonstrated that exposing myeloma cell lines ARH-77 and RPMI-8226 to ZOL inhibits cell growth in a dose-dependent but not a time-dependent manner and that combination of Dex and Thal with ZOL induces apoptotic cell death, providing a rationale for potential applications in vivo.
Similar content being viewed by others
References
Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease.Drugs. 1991;42:919–944.
Berenson J, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.N Engl J Med. 1996;334:488–493.
McCloskey E, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma.Br J Haematol. 1998;100: 317–325.
Lövik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groat H, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors in to mature osteoclasts: the effect of a bisphosphonate.J Bone Miner Res. 1988;3:185–192.
Hughes DE, Mac Donald BR, Russel RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.J Clin Invest. 1989;83:1930–1935.
Sato M, Grassor G, Endo N, et al. Bisphosphonate action: alen- dronate localization in rat bone and effects on osteoclast ultra- structure.J Clin Invest. 1991;88:2095–2105.
Carano A, Teitelbaym SA, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.J Clin Invest. 1990;85:456–461.
Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.Br J Haematol. 2002;116:278–290.
Shipman CM, Rogers MJ, Apperley JF, Russel RGG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.Br J Haematol. 1997;98:665–672.
Aparicia A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.Leukemia. 1998;12:220–229.
Shipman CM, Rogers MJ, Apperley JF, Russel RGG, Craucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells.Leuk Lymphoma. 1998;32:129–138.
Berenson J, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.J Clin Oncol. 1998;16: 593–602.
Mundy GR,Yoneda T. Bisphosphonates as anticancer drugs.N Engl J Med. 1998;339:398–400.
Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo.Br J Haematol. 1998;103:530–532.
Kunzmann V, Bauer E, Feurle J, WeiBinger F, Tony HP, Wilhelm M. Stimulation of T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.Blood. 2000;96: 384–392.
Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000;96:2943–2950.
Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process.Blood. 1998;91:3–21.
Corral LG, Haslett PAJ, Muller GW. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α.J Immunol. 1999;163: 380–386.
Ferrari M, Fornasiero MC, Isetta AM. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro.J Immunol Methods. 1990;131:165–172.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi CA. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.J Immunol Meth. 1991;139:271–279.
Rogers MJ, Chilton KM, Caxon FP, Smith MO, Suri S, Russel GG. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.J Bone Miner Res. 1996;11:1482–1491.
Selander KS, Mönkkönen J, Karhukorpi EK, Harkönen P, Hannuniemi R, Vaananem K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.Mol Pharmacol. 1996; 50:1127–1138.
Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry.Cytometry. 1992;13:795–808.
Rogers MJ, Watts DJ, Russel RG, et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.J Bone Miner Res. 1994;9:1029–1039.
Cecchini MG, Felix H, Fleisch H, Cooper PH. Effects of bisphosphonates on proliferation and viability of mouse bone marrow- derived macrophages.J Bone Miner Res. 1987;2:135–142.
Zaida M, Datta HK, Patchell A, Moonga B, Muclntyre I. Calcium- activated intracellular calcium elevation: a novel mechanism of osteoclast regulation.Biochem Biophys Res Commun. 1989;159: 68–71.
Ning ZQ, Murphy JJ. Calcium ionophore-induced apoptosis of human B cells is preceded by the induced expression of early response genes.Eur J Immunol. 1993;23:3369–3372.
Ojeda F, Guarda MI, Maldonado C, Folch H. Protein kinase C involvement in thymocyte apoptosis induced by hydrocortisone.Cell Immunol. 1990;125:535–542.
Kameda T, Ishikawa H, Tustsni T. Detection and characterization of apoptosis in osteoclasts in vitro.Biochem Biophys Res Commun. 1995;207:753–760.
Sarih M, Sauvannavong V, Adam A. Nitric oxide synthase induces macrophage death by apoptosis.Biochem Biophys Res Commun. 1993;191:503–508.
Nyugen T, Brunson D, Crespi CI, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide.Proc NatlAcad Sci USA. 1992;89:3030–3034.
Davies EF, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cyto- toxicity in multiple myeloma.Blood. 2001;98:210–216.
Hatfill SJ, Fester ED, DeBeer DP, Bohm L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites.Leuk Res. 1991;15:129–136.
Marks MG, Shi J, Fry MO, et al. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioal- lantoic membrane (CAM) assay and on tumor and endothelial cell proliferation.Biol Pharm Bull. 2002;25:597–604.
Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma.Blood. 1995;85:863–872.
Hardin J, Macleod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death.Blood. 1994;84: 3063–3070.
Raisz LG, Cooper RA, Schechter GP, Salmon S. Evidence for the secretion of an osteoclast stimulating factor in myeloma.N Engl J Med. 1974;291:1041–1046.
Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, Berenson JR. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract].Blood. 1996; 88:105a.
Tassone P, Forciniti S, Galea E, et al. Growth inhibition and syner- gistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.Leukemia. 2000;14:841–844.
Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.Mol Med. 1996;2:506–515.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ural, A.U., Yilmaz, M.I., Avcu, F. et al. The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide. Int J Hematol 78, 443–449 (2003). https://doi.org/10.1007/BF02983818
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983818